Neoplasia

Papers
(The H4-Index of Neoplasia is 28. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Epitranscriptomic mechanisms of androgen signalling and prostate cancer1512
ARID1A loss sensitizes colorectal cancer cells to floxuridine109
Single cell analysis unveils the commonality and heterogeneity between nasopharyngeal and oropharyngeal carcinoma87
Corrigendum to “Structure-function studies of the bHLH phosphorylation domain of TWIST1 in prostate cancer cells” [Neoplasia 17 (2014) 85]52
Visualizing mast cell migration to tumor sites using sodium iodide symporter of nuclear medicine reporter gene52
Corrigendum to “Tumorigenicity of IL-1α- and IL-1β-Deficient Fibrosarcoma Cells” [Neoplasia, Volume 10, Issue 6, June 2008, Pages 549–562]49
Sialylated IgG-activated integrin β4-Src-Erk axis stabilizes c-Myc in a p300 lysine acetyltransferase-dependent manner to promote colorectal cancer liver metastasis44
High metastatic tumor-derived CXCL16 mediates liver colonization metastasis by inducing Kupffer cell polarization via the PI3K/AKT/FOXO3a pathway41
Therapeutic benefit of the dual ALK/FAK inhibitor ESK440 in ALK-driven neuroblastoma41
The GSK3 kinase and LZTR1 protein regulate the stability of Ras family proteins and the proliferation of pancreatic cancer cells39
5-Aza-2′-deoxycytidin (Decitabine) increases cancer-testis antigen expression in head and neck squamous cell carcinoma and modifies immune checkpoint expression, especially in CD39-positive CD8 and CD39
RUNX2 enhances bladder cancer progression by promoting glutamine metabolism38
L-methionine promotes CD8+ T cells killing hepatocellular carcinoma by inhibiting NR1I2/PCSK9 signaling38
Role of heparanase 2 (Hpa2) in gastric cancer37
Combination of sunitinib and 177Lu-labeled antibody cG250 targeted radioimmunotherapy: A promising new therapeutic strategy for patients with advanced renal cell cancer36
Tumor-Infiltrating Immune Cells in Colorectal Cancer36
Combined radio-immunotherapy: An opportunity to increase the therapeutic ratio of oligometastasis-directed radiotherapy36
Myxoid glioneuronal tumor: Histopathologic, neuroradiologic, and molecular features in a single center series36
Time-restricted feeding affects the fecal microbiome metabolome and its diurnal oscillations in lung cancer mice33
Retraction notice to “Role of Autophagy as a Survival Mechanism for Hypoxic Cells in Tumors” [Neoplasia 18 (2016) 347- 355/201]33
Mutational signatures and their association with survival and gene expression in urological carcinomas32
Advanced progress of spatial metabolomics in head and neck cancer research31
From adenoma to CRC stages: the oral-gut microbiome axis as a source of potential microbial and metabolic biomarkers of malignancy31
Epigenetic DNA modifications and vitamin C in prostate cancer and benign prostatic hyperplasia: Exploring similarities, disparities, and pathogenic implications31
Colorectal cancer, Vitamin D and microbiota: A double-blind Phase II randomized trial (ColoViD) in colorectal cancer patients30
Identification of recurrent BRAF non-V600 mutations in intraductal carcinoma of the prostate in Chinese populations29
Innate immunity: Looking beyond T-cells in radiation and immunotherapy combinations29
Leptomeningeal dissemination in pediatric brain tumors29
Lactate promoted cisplatin resistance in NSCLC by modulating the m6A modification-mediated FOXO3/MAGI1-IT1/miR-664b-3p/IL-6R axis28
0.055565118789673